Advancing precision medicine with molecular glues

Magnet Biomedicine's modular TrueGlue™ technology enables the systematic discovery of molecular glues toward the treatment of human disease.

Graphic Shape
Graphic Shape
Graphic line Shape
Magnet Biomedicine scientist in the lab pipetting.

The Science

TrueGlues are specialized small molecule therapeutics that induce proximity between a disease-relevant target and a “presenter” protein, resulting in novel presenter-dependent biology.

Magnet is advancing precision medicine through the systematic design of molecular glues capable of inducing novel protein-protein interactions (PPIs) and unlocking novel biology. Magnet's TrueGlueTM platform enables the rational selection of protein pairs and the systematic design of molecular glues to achieve unprecedented therapeutic goals.

3D schema outlining the mechanism by which TrueGlues engage with presenter proteins and disease targets.

When a TrueGlue binds to a presenter protein, a neo-PPI interface is created, mediating the formation of a ternary complex with a disease target protein, and resulting in presenter-dependent engagement of the target protein.

TrueGlues offer the potential to deliver therapies for even the most intractable targets and to achieve other desirable but challenging translational goals:

  • Novel PPIs can overcome limitations in ligandability of target proteins
  • Tissue specificity of a presenter can minimize on-target-off-tissue toxicity
  • Extracellular presenters can enable glue inhibitors of cytokines/receptors to substitute oral small molecules for injectable biologics

Since their discovery more than three decades ago, molecular glues have demonstrated vast potential to treat human disease.

Magnet is redefining the potential of molecular glues by looking beyond E3 ligases and exploring the broader protein landscape. By strategically pairing target proteins with endogenous presenter proteins, we can explore additional MOAs, unlock novel therapeutic possibilities, and pioneer new treatment paradigms.

Uniquely enabled by its platform capabilities, Magnet is pioneering the discovery of novel molecular glue medicines to address a range of indications with high unmet need in cancer and immune disorders.

Graphic Shape
Graphic Shape
Graphic line Shape

OUR TECHNOLOGY

Building upon recent advances in proteomics, screening, and bioinformatics, we believe that leveraging these advances will enable our goal of rational molecular glue discovery and development.

Magnet's TrueGlue™ discovery platform utilizes state-of-the-art screening technologies, proprietary chemical libraries, and strategic selection of target and presenter proteins to rationally and systematically identify TrueGlues™. These small molecules induce proximity and promote cooperativity between proteins, enabling precise drug targeting to disease-relevant tissues and addressing historically difficult-to-drug proteins.

Magnet Biomedicine scientist in a lab pipetting into a conical centrifuge tube.

OUR PEOPLE

Magnet’s team combines decades of drug discovery experience.

Our diverse scientific expertise has enabled a multipronged approach that pushes the boundaries of existing technology to advance TrueGlues as a therapeutic modality with the potential to alter the treatment landscape in cancer and autoimmune diseases.

Brian Safina Headshot

Brian Safina, PhD

President & Chief Executive Officer
bret williams headshot

Bret Williams, PhD

Senior Vice President of Research
matthew-hayward-headshot

Matthew Hayward, PhD

Vice President of Drug Discovery
jennifer-franklin-headshot

Jennifer Franklin

Vice President of Operations
kristina-burow-headshot

Kristina Burow

Managing Director at ARCH Venture Partners
Thomas Cahill headshot

Thomas Cahill, MD, PhD

Founder and Managing Partner at Newpath Partners
Seiji Miyahara Headshot

Seiji Miyahara, PhD

Partner & Senior Investment Director at Taiho Ventures
ramnik-xavier-headshot

Ramnik Xavier, MD, PhD

Scientific Advisory Board Chair
Benjamin F. Cravatt headshot

Benjamin F. Cravatt, PhD

Founder & Advisor
David A. Spiegel headshot

David A. Spiegel, MD, PhD

Founder & Advisor
Michael Rosbash

Michael Rosbash, PhD

Founder & Advisor
 Richa Saxena headshot

Richa Saxena, PhD

Founder & Advisor
Stuart Schreiber headshot

Stuart Schreiber, PhD

Founder & Advisor
Joshua Alper Headshot

Joshua Alper, PhD

Biomolecular Discovery
Chelsea Ankeny headshot

Chelsea Ankeny

Office Manager
Douglas Beshore Headshot

Douglas Beshore, PhD

Chemistry
Austin Carr headshot

Austin Carr, PhD

Proteomics
Gina Chen Headshot

Gina Chen

Chemistry
Xiao Chen headshot

Xiao Chen, PhD

Biology
YiQun Chen headshot

YiQun Chen

Biology
Diala Ezzeddine Headshot

Diala Ezzeddine, PhD

Business Development
Jessica Gasser headshot

Jessica Gasser, PhD

Biology
Shubhroz Gill headshot

Shubhroz Gill, PhD

Biology
Adarsh Godbole Headshot

Adarsh Godbole

Protein Production
Yuan Hu Headshot

Yuan Hu, PhD

Computational Chemistry
Bruce Hua headshot

Bruce Hua, PhD

Chemistry
Liam Hudson headshot

Liam Hudson, PhD

Chemistry
Anita Kim headshot

Anita Kim

Lab Operations
Chueh-Ling Kuo headshot

Chueh-Ling Kuo, PhD

Biomolecular Discovery
Na Li headshot

Na Li

Biology
Jason Lowe headshot

Jason Lowe, PhD

Chemistry
Alyssa Lutservitz headshot

Alyssa Lutservitz, MS

Informatics
Jessica McManus Headshot

Jessica McManus

Biology
Francesca Pisanzio headshot

Francesca Pisanzio

Biology
James Ralff headshot

James Ralff

Compound Management
Andrew Reidenbach headshot

Andrew Reidenbach, PhD

Biomolecular Discovery
Anthony Scruse Headshot

Anthony Scruse, PhD

Chemistry
Luke Stamatakis headshot

Luke Stamatakis, CPA

Finance & Accounting
Tom Tian headshot

Tom Tian, PhD

Biology
Tiffany Tsang headshot

Tiffany Tsang, PhD

Biology
Go Watanabe headshot

Go Watanabe, PhD

Protein Production
Teruki Watanabe Headshot

Teruki Watanabe, PhD

Chemistry
Lauren Weiss Headshot

Lauren Weiss

Biology
Hsin-Lan Wen headshot

Hsin-Lan Wen, PhD

Biology
Graphic line Shape
Graphic Blob Shape

CAREERS

Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our founders.

We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.

Stay tuned for future job openings.

Graphic line Shape
Graphic Shape

News

The latest Magnet news and presentations

02.28.2025

Magnet Biomedicine Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Novel Molecular Glue Medicines

09.20.2023

Magnet Biomedicine Emerges from Stealth with $50 Million to Advance Rational Approach to Molecular Glues with TrueGlue™ Discovery Platform